Cakiroglu Basri, Arda Ersa, Tas Tuncay, Senturk Aykut Bugra
Department of Urology, Hisar Intercontinental Hospital, Istanbul, Turkey.
Department of Urology, Private Esencan Hospital, Istanbul, Turkey.
Afr J Paediatr Surg. 2018 Jul-Dec;15(3):131-134. doi: 10.4103/ajps.AJPS_115_16.
The purpose of this study was to compare the rates of success, relapse, and compliance to treatment in patients undergoing alarm therapy or receiving desmopressin for primary monosymptomatic nocturnal enuresis (PMNE).
This retrospective study was performed by reviewing the medical files of patients undergoing alarm therapy (Group 1) or receiving desmopressin (Group 2) for PMNE, between January 2010 and July 2014. Patients undergoing treatment in the 3 and 6 month as well as 1 year follow-up data were analyzed. Two groups were compared with regard to treatment success, relapse rate, and compliance to treatment.
Group 1 included 64 and Group 2 included 70 children. Relapse rates at the 3 month, 6 month, and 1 year were 67.2%, 71.9%, and 17.0% for Group 1 and 74.3%, 80.0%, and 21.4% for Group 2, respectively. There was no statistically significant difference between relapse rates at any point of follow-up.
Alarm therapy and desmopressin have the same success rate and relapse rates for PMNE. Compliance with alarm therapy is higher and we recommend it as the first-line treatment. On the other hand, desmopressin has low side effects and can also be used.
本研究旨在比较接受警报疗法或去氨加压素治疗原发性单症状性夜间遗尿症（PMNE）患者的成功率、复发率及治疗依从性。
本回顾性研究通过查阅2010年1月至2014年7月间接受警报疗法（第1组）或去氨加压素治疗（第2组）的PMNE患者的医疗档案进行。分析患者在治疗后3个月、6个月以及1年随访的数据。比较两组在治疗成功率、复发率及治疗依从性方面的差异。
第1组有64名儿童，第2组有70名儿童。第1组在3个月、6个月和1年时的复发率分别为67.2%、71.9%和17.0%，第2组分别为74.3%、80.0%和21.4%。在任何随访时间点，两组的复发率均无统计学显著差异。
警报疗法和去氨加压素治疗PMNE的成功率和复发率相同。警报疗法的依从性更高，我们推荐将其作为一线治疗方法。另一方面，去氨加压素副作用小，也可使用。
